What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Asthma
- Disease
His main research concerns Asthma, Immunology, Internal medicine, Placebo and Allergy.
His biological study spans a wide range of topics, including Anesthesia, Exacerbation, Randomized controlled trial, Intensive care and Physical therapy.
His study in Immunology is interdisciplinary in nature, drawing from both Bronchoalveolar lavage and Airway.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Omalizumab.
His Placebo research also works with subjects such as
- Surgery which intersects with area such as Rheumatoid arthritis,
- Clinical endpoint that connect with fields like Lebrikizumab.
His Allergy research is multidisciplinary, relying on both Family medicine and Immunopathology.
His most cited work include:
- Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) (3245 citations)
- Asthma. From bronchoconstriction to airways inflammation and remodeling. (1529 citations)
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program (1383 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Asthma, Immunology, Internal medicine, Placebo and Eosinophil.
William W. Busse studies Fluticasone propionate which is a part of Asthma.
His work on Immunology is being expanded to include thematically relevant topics such as Airway.
His Internal medicine study combines topics in areas such as Gastroenterology, Omalizumab and Endocrinology.
His Eosinophil research is multidisciplinary, incorporating elements of Molecular biology and Bronchoalveolar lavage.
His research integrates issues of Dry-powder inhaler and Bronchodilator in his study of Anesthesia.
He most often published in these fields:
- Asthma (54.53%)
- Immunology (44.00%)
- Internal medicine (25.86%)
What were the highlights of his more recent work (between 2014-2021)?
- Asthma (54.53%)
- Internal medicine (25.86%)
- Immunology (44.00%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Asthma, Internal medicine, Immunology, Omalizumab and Placebo.
His work carried out in the field of Asthma brings together such families of science as Exacerbation, Immunoglobulin E and Intensive care medicine.
His work on Adverse effect, Severe asthma and Corticosteroid as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
His studies deal with areas such as Gene expression and Airway as well as Immunology.
The various areas that William W. Busse examines in his Omalizumab study include Clinical effectiveness, Observational study, Allergic asthma and Asthma exacerbations.
His research in Placebo intersects with topics in Randomized controlled trial, Randomization, Intention-to-treat analysis, Rate ratio and COPD.
Between 2014 and 2021, his most popular works were:
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial (564 citations)
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma (501 citations)
- Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. (283 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Asthma
- Disease
The scientist’s investigation covers issues in Asthma, Immunology, Internal medicine, Intensive care medicine and Omalizumab.
His Asthma research includes themes of Exacerbation, Adverse effect and Disease.
His Immunology study combines topics from a wide range of disciplines, such as Differentially methylated regions and DNA methylation.
William W. Busse interconnects Gastroenterology and Placebo in the investigation of issues within Internal medicine.
The Placebo study combines topics in areas such as Rate ratio, Anesthesia and Randomized controlled trial.
His Intensive care medicine research incorporates elements of Inhaled corticosteroids, β2 agonists, Maintenance therapy and Allergy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
